Home

Beech Tree Labs, Inc. specializes in the discovery and early-stage development of pharmaceutical formulations that address chronic disorders. The Company’s lead product candidate is BTL-slo, an agent that targets adhesions, scars, and fibrosis.

An IND has been filed to use BTL-slo in a clinical trial focusing on treatment of adhesions arising from total knee replacement surgery. To date there are no other pharmacological options approved or in development to treat these adhesions. Total peak year sales of BTL-slo for knee and other surgical adhesions are estimated at $1.2 billion. Patents have issued in the U.S. and in major international markets for many of these indications.

Enhancing its economic value, BTL-slo has been combined with another molecule, BTL-stcf, and patented for the treatment of COPD. The current market for drugs to treat COPD reaches $11 billion worldwide, even though these drugs only treat the symptoms of the disease. Beech Tree’s drug candidate could be the first with a mechanism of action to slow or even reverse scarring and loss of lung function, with projected peak year sales of $4.4 billion worldwide.

Additional product candidates include BTL-tml, an anti-viral demonstrating efficacy for herpesvirus infections and BTL-hs, a formulation addressing muscle weakness disorders such as urinary incontinence.

NEWS — April 2020

Beech Tree Labs is developing a potential antiviral therapy to fight COVID-19 pandemic.

Novel, low-dose resonant molecular signaling (RMS) technology may reduce virus infectivity and neutralize the cytokine storm that often characterizes COVID-19. Beech Tree Labs is evaluating one of its microdosed formulations, TML, to alleviate symptoms induced by Sars-cov-2.

Beech Tree Labs sponsored two Phase 2 clinical trials that demonstrated the safety and efficacy of TML to reduce the onset of Herpes virus lesions after exposure to dental procedure or sunlight. The p value of the combined studies was 0.019. No adverse effects were observed.

Twenty coronavirus symptomatic outpatients have been treated with TML anecdotally. All have responded positively with remission of symptoms within 4 to 48 hours with no adverse side effects and no relapse. Some of the patients who used TML are physicians.

TML is administered by sublingual drops. TML contains a microdose of thimerosal. In a seven day course therapy, the total amount of TML is 1/10 of the amount of TML in one dose of vaccine.

Beech Tree Labs is preparing for a pilot double blind placebo-controlled study with symptomatic outpatients. The Investigational New Drug (IND) application necessary to obtain FDA’s approval to conduct clinical trials is in preparation which will allow Beech Tree Labs to move on quickly from the pilot study to a Phase 3 trial.

Copyright Beech Tree Labs, Inc.